抗脂综合征治疗中,S-基洛昆可以防止抗脂血栓性复合体的发生
Ming-Shou Hsieh1, Heng-Wei Liu2, Fu-You Guo3
1Department of Medical Research & Education, Taipei Medical University- Shuang Ho Hospital, New Taipei 23561, Taiwan.
概括
氧化 (S-HCQ) 的S-enantiomer在预防与抗脂综合征 (APS) 相关的血栓形成和内皮功能障碍方面表现出卓越的疗效. 这项研究强调了S-HCQQ.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 用于全身性红斑狼 (SLE) 的氧化 (HCQ) 通过抑制抗β2-糖蛋白I (anti-β2GPI) 抗体具有抗血栓作用.
- HCQ是一种种族混合物;只有一个反体提供治疗效益,而另一个可能会导致毒性.
- 抗脂综合征 (APS) 具有抗脂抗体的特征,导致血栓形成和内皮功能障碍.
研究的目的:
- 为了评估R-enantiomer 氧化 (R-HCQ),S-enantiomer 氧化 (S-HCQ) 和赛血 HCQ (Rac-HCQ) 的血栓预防疗效.
- 评估HCQ反体对抗脂综合征 (APS) 相关标记物和内皮功能障碍的影响.
- 为了比较S-HCQ与R-HCQ在破坏β2GPI/抗β2GPI相互作用方面的疗效.
主要方法:
- 使用人类静脉内皮细胞 (HUVEC) 的体外研究.
- 在体内研究使用与人类β2-葡萄糖蛋白I抗体免疫的小鼠.
- 评估抗脂血栓复合体形成和调节的HCQ反体.
主要成果:
- 在实验室中,S-HCQ显著降低了β2GPI复合体的结合,并恢复了AnxA5抗凝剂屏蔽.
- 在HUVEC中,S-HCQ减弱了促炎细胞因子和内皮激活标记物,缓解了内皮功能障碍.
- 在APS小鼠模型的股骨静脉中,S-HCQ有效地减少了凝块的形成.
结论:
- 与R-HCQ和Rac-HCQ相比,S-HCQ在破坏β2GPI/anti-β2GPI相互作用和预防血栓形成方面表现出更高的疗效.
- 通过减少炎症,氧化应激和血栓形成活性,S-HCQ可以缓解APS中的内皮功能障碍.
- S-HCQ 具有作为治疗抗脂综合征的有针对性的治疗替代品的潜力.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
441
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
441
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
140
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
140
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
121
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
121